Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia

Virus Research

Volumn 137, Issue 1, 2008, Pages 168-172

  Shahmahmoodi, Shohreh ^a   Parvaneh, Nima ^b   Burns, Cara ^c   Asghar, Humayun ^d   Mamishi, Setareh ^b   Tabatabaie, Hamideh ^a   Chen, Qi ^c   Teimourian, Shahram ^b   Gooya, Mohammad Mehdi ^e   Esteghamati, Abdol Reza ^e   Mousavi, Taha ^e   Yousefi, Maryam ^a   Farrokhi, Kobra ^a   Mashlool, Maryam ^e   Kew, Olen ^c   Nategh, Rakhshandeh ^a  

^a Institute of Public Health Research   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Iran; Vaccine derived poliovirus; VDPV; X linked agammaglobulinemia

Indexed keywords

IMMUNOGLOBULIN; ORAL POLIOMYELITIS VACCINE; PROTEIN VP1;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; FLACCID PARALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IRAN; MALE; NUCLEOTIDE SEQUENCE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPERATURE SENSITIVITY; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; VIRUS ISOLATION; X LINKED AGAMMAGLOBULINEMIA;

AGAMMAGLOBULINEMIA; CAPSID PROTEINS; CELL LINE, TUMOR; GENETIC DISEASES, X-LINKED; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INFANT; IRAN; MALE; MOLECULAR SEQUENCE DATA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

MIRIDAE; POLIOVIRUS;

EID: 49849085834     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2008.07.006     Document Type: Article

References (42)

1. Alexander Jr. J.P., Gary Jr. H.E., and Pallansch M.A. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175 (1997) S176-S182
2. Bellmunt A., May G., Zell R., Pring-Akerblom P., Verhagen W., and Heim A. Evolution of poliovirus type I during 5, 5 years of prolonged enteral replication in an immunodeficient patient. Virology 265 (1999) 178-184
3. Blomqvist S., Savolainen C., Laine P., Hirttio P., Lamminsalo E., Penttila E., Joks S., Roivainen M., and Hovi T. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78 (2004) 4876-4883
4. Brown B.A., Oberste M.S., Maher K., and Pallansch M. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the non-capsid coding region. J. Virol. 77 (2003) 8973-8984
5. Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., Soresina A.R., Vivarelli R., Delpeyroux F., Martín J., and Fiore L. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 84 (2003) 1215-1221
6. Centers for Disease Control Prevention. Update on vaccine-derived polioviruses. Morbid. Mortal. Wkly. Rep. 55 (2006) 1093-1097
7. Centers for Disease Control Prevention. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. Morbid. Mortal. Wkly. Rep. 56 (2007) 996-1001
8. Dowdle W.R., de Gourville E., Kew O.M., Pallansch M.A., and Wood D.J. Polio eradication: the OPV paradox. Rev. Med. Virol. 13 (2003) 277-291
9. Dunn G., Begg N.T., Cammack N., and Minor P.D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 32 (1990) 92-95
10. Gavrilin G.V., Cherkasova E.A., Lipskaya G.Y., Kew O.M., and Agol V.I. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J. Virol. 74 (2000) 7381-7390
11. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenia M.A., da Silva E., Khan A.J., Webster A.D.B., Minor P.D., Dunn G., Asturias E., Hussain H., Pallansch M.A., Kew O.M., Winkelstein J., Sutter R., and The Polio Project Team. Search for poliovirus carriers in persons with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. WHO 82 (2004) 3-8
12. Jorba J., Campagnoli R., De L., and Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J. Virol. 82 (2008) 4429-4440
13. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., and Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59 (2005) 587-635
14. Kew O.M., Sutter R.W., Nottay B., McDonough M., Prevots D.R., Quick L., and Pallansch M. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36 (1998) 2893-2899
15. Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., and Sutter R.W. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188 (2003) 1845-1852
16. Kilpatrick D.R., Nottay B., Yang C.-F., Yang S.-J., da Silva E., Peñaranda S., Pallansch M., and Kew O. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 36 (1998) 352-357
17. Kilpatrick D.R., Nottay B., Yang C.-F., Yang S.-J., Mulders M.N., Holloway B.P., Pallansch M.A., and Kew O.M. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 34 (1996) 2990-2996
18. Liu H.-M., Zheng D.-P., Zhang L.-B., Oberste M.S., Pallansch M.A., and Kew O.M. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J. Virol. 74 (2000) 11153-11161
19. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martín J., O'Leary P., Thompson R.A., Osman H., Wood P., Minor P., Wood D.J., and Pillay D. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363 (2004) 1509-1513
20. Mamishi, S., Shahmahmoudi, S., Tabatabaie, H., Teimourian, S., Pourakbari, B., Gheisari, Y., Yeganeh, M., Salavati, A., Esteghamati, A.-R., Gooya, M.M., Nategh, R., Parvaneh, N., in press. Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. Eur. J. Pediatr. doi:10.1007/s00431-008-0674-5.
21. Martín J., Dunn G., Hull R., Patel V., and Minor P.D. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74 (2000) 3001-3010
22. Martín J., Odoom K., Tuite G., Dunn G., Hopewell N., Cooper G., Fitzharris C., Butler K., Hall W.W., and Minor P.D. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78 (2004) 13839-13847
23. Minor P.D. The molecular biology of poliovaccines. J. Gen. Virol. 73 (1992) 3065-3077
24. Minor P.D., Dunn G., Evans D.M.A., Magrath D.I., John A., Howlett J., Phillips A., Westrop G., Wareham K., Almond J.W., and Hogle J.M. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J. Gen. Virol. 70 (1989) 1117-1123
25. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B.L., Kameda A., Itoh H., Arita M., Wimmer E., and Nomoto A. Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 58 (1986) 348-358
26. Parvaneh N., Shahmahmoudi S., Tabatabai H., Zahraei M., Mousavi T., Esteghamati A.-R., Gooya M.M., Mamishi S., Nategh R., and Kew O.M. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J. Clin. Virol. 39 (2007) 145-148
27. Paul A.V., Mugavero J., Yin J., Hobson S., Schultz S., van Boom J.H., and Wimmer E. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272 (2000) 72-84
28. Pipkin P.A., Wood D.J., Racaniello V.R., and Minor P.D. Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J. Virol. Methods 41 (1993) 333-340
29. Rosen F.S., Cooper M.D., and Wedgwood R.J.P. The primary immunodeficiencies. N. Engl. J. Med. 333 (1995) 431-440
30. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
31. Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew O.M., Pallansch M.A., Orenstein W.A., and Hinman A.R. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14 (1992) 568-579
32. Sutter R.W., Kew O.M., and Cochi S.L. Poliovirus vaccine-live. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), W.B. Saunders Company, Philadelphia 631-685
33. Sutter R.W., and Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 11 (1994) 426-438
34. van der Avoort H.G.A.M., Hull B.P., Hovi T., Pallansch M.A., Kew O.M., Crainic R., Wood D.J., Mulders M.N., and van Loon A.M. A comparative study of five methods of intratypic differentiation of polioviruses. J. Clin. Microbiol. 33 (1995) 2562-2566
35. World Health Organization. Polio Laboratory Manual. 4th edition (2004), World Health Organization, Geneva
36. World Health Organization. WHO Vaccine-Preventable Diseases: Monitoring System, 2006 Global Summary (2006), World Health Organization, Geneva, Switzerland
37. World Health Organization. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2006-June 2007. Wkly. Epidemiol. Rec. 82 (2007) 322-328
38. World Health Organization. Progress towards interrupting of wild poliovirus transmission worldwide, January 2007-April 2008. Wkly. Epidemiol. Rec. 83 (2008) 170-176
39. World Health Organization. Progress towards poliomyelitis eradication in Afghanistan and Pakistan, January-December 2007. Wkly. Epidemiol. Rec. 83 (2008) 109-115
40. Yakovenko M.L., Cherkasova E.A., Rezapkin G.V., Ivanova O.E., Ivanov A.P., Eremeeva T.P., Baykova O.Y., Chumakov K.M., and Agol V.I. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80 (2006) 2641-2653
41. Yang C.-F., Chen H.-Y., Jorba J., Sun H.-C., Yang S.-J., Lee H.-C., Huang Y.-C., Lin T.-Y., Chen P.-J., Shimizu H., Nishimura Y., Utama A., Pallansch M., Miyamura T., Kew O., and Yang J.-Y. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79 (2005) 12623-12634
42. Yang C.-F., Naguib T., Yang S.-J., Nasr E., Jorba J., Ahmed N., Campagnoli R., van der Avoort H., Shimizu H., Yoneyama T., Miyamura T., Pallansch M.A., and Kew O. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983-1993. J. Virol. 77 (2003) 8366-8377